Sell:0.30pBuy:0.40p0.04p
(11.43%)
Ananda Pharma plc is a United Kingdom-based company focused on the development and commercialization of cannabidiol (CBD)-based therapies. It is engaged in developing medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with chemotherapy induced peripheral neuropathy (CIPN) & endometriosis) and Heart Failure with preserved Ejection Fraction (HFpEF). ACTiON is a Phase II, double blind placebo-controlled crossover randomized clinical trial (RCT) to assess its MRX1 drug candidate versus placebo in the treatment of CIPN. ENDOCAN-1 shall help determining whether a cannabinoid can reduce endometriosis-associated pain. HFpEF is a study designed to evaluate the cardioprotective effects of its MRX1 drug candidate in a preclinical HFpEF model. Its two novel cannabinoid medicines: MRX2 (CBD) and MRX2T, helps in a range of seizure types and epilepsies in children and adults.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.